DAFTAR PUSTAKA

1. World Health Organisation. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018.

2. Dinihari TN, Siagian V. Pedoman Nasional Pengendalian Tuberculosis. Jakarta: Kementerian Kesehatan RI 2014.

3. Lienhardt C, Mnneh K, Bouchier V, Lahai G, Milligan PJM, McAdam KPJW. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia.INT J TUBERC LUNG DIS 1998; 2(9):712-718.

4. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factor predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. INT J TUBERC LUNG DIS 2003; 7(1):58-64.

5. Amaral EP, Lasunkaia EB, Regina M. Innate immunity: how to sensing of mycobacteria and tissue damage modulates macrophage death. Microbe and infection 2015; XX: 1-10.

6. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, Aliberti J. Host control of *Mycobacterium Tuberculosis*is regulated by 5 -lipoxygenase-dependent *Lipoxin* production. J Clin Invest 2005;115:1601-6.

7. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen Therapy Resulted in Significantly Decreased Tissue Bacillary Loads and Increased Survival in a New Murine Experimental Model of Active Tuberculosis. JID 2015; 208: 199-202.

8. Soolingen DV, Hoogenboezem T, Hass PEWD, Hermans PWM, Koedam MA, Teppema KS, Breannan PJ, et al. A Novel Pathogenic Taxon of the *Mycobacterium Tuberculosis*Complex Canetti: Characterization of an Exceptional Isolate from Africa. INT. J. SYST. BACTERIOL. 1997; 47(4): 1236-1245.

9. Sharma N, Nautiyal SC, Kaur P, Singh D, Kauskhik R, Singh P, et al. Advent in technologies for molecular diagnosis of tuberculosis. Adv.Appl. Sci. Res. 2013;4(#):146-149.

10. Parle A, Singh G. Treatment and advances in tuberculosis research. International Journal of Pharmaceutical Science and Research 2017; 2(4): 14-21.

11. Gordon SVand Parish T. Microbe Profile: *Mycobacterium tuberculosis*: Humanity's deadly foe. Microbiology 2018; 164:437-439.

12. Dannenberg AM, Tomashefki JF. Patogenesis of pulmonary tuberculosis in pulmonary disease and disorders. 2nd ed. New York: Fishman AP (Ed), McGraw-Hill 1988. Vol 3.

13. Weiss G, Scahible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev 2015; 264:182.

14. De Jonge MI, Pehau-Amaudet G, Fretz MM. ESAT-6 from *Mycobacterium Tuberculosis*dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol 2015; 129:1287.

15. Riley LW, Reyn CFV, Baron EL. Immunology of tuberculosis. UpTodate 2017: Ver. 13.0. Topic 8026.

16. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long, R,Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148–55.

17. Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014;14: 81-93.

18. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.

19. Chung EY, Kim SJ, Ma XJ. Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res 2006;16:154-61.

20. Riendeau CJ, Kornfeld H. THP-1 Cell Apoptosis in Responsse to Mycobacterial Infection. Infection and immunity 2003;71: 254–259.

21. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade. Cell 1997; 91: 479–489.

22. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007; 32:37-43.

23. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responsses. J Biol Chem 2003; 278:51613-21.

24. Berghe TV, Vanlangenakker N, Parthoens E, Ceckers W, Devos M, Festjens N, et al. Necroptosis, necrosis and secondary necrosis converge on similarcellular disintegration features. Cell Death Differ 2010; 17:922-30.

25. Vandenabeele P, Galluzzi L, Berghe TV, Kroemer, G. Molecular mechanisms of necroptosis: an ordered cellular explosion.Cell Death Differ 2010;11: 700-714.

26. Srinivasan L, Ahlbrand S, Briken V. Interaction of *Mycobacterium Tuberculosis*with Host Cell Death Pathways. Cold Spring Harb Perspect Med 2014;4:a022459.

27. Dietzold J, Gopalakrishnan A, Salgame, P. Duality of lipid mediators in host responsse against Mycobacterium tuberculosis: good cop, bad cop. F1000Prime 2015:7; 29.

28. Romano M, Cianci E, Simiele F, Recchiuti A. "*Lipoxin*s and aspirin-triggered *Lipoxin*s in resolution of inflammation". European Journal of Pharmacology 2015: 760; 49–63.

29. Critchley JA., Young F., Orton L., Garner P., 2013.Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis; 13:223-37

30. Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochemical and Biophysical Research Communications 1984: 118 (3); 943–9.

31. Qu Q, Xuan W, Fan GH. Roles of resolvins in the resolution of acute inflammation. Cell Biology International 2015;39 (1): 3–22

32. Serhan CN. *Lipoxin*s and aspirin-triggered 15-epi-*Lipoxin*s are the firstlipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005;73:163e77.

33. Bonnans C, Gras D, Chavis C, Mainprice B, Vachier I, Godard P, et al.Synthetis and anti-inflammatory effect of *Lipoxin*s in human airway epitelial cells.Biomedicine & Pharmacotherapy 2007:61; 261-267.

34. Goicoechea M, Nino MDS, Ortiz A, Vinuesa SGD, Quiroga B, Bernis C, et al.Low dose aspirin increase 15-epi-*Lipoxin* A4 levels in diabetic chronic kidney disease patients.Prostaglandins, Leukotrienes and Essential Fatty Acids 2017:125;8–13.

35. Kaviarasan Ka, Jithu M, Mulla MA, Sharma T, Sivasankar S, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2

cytokine balance are potential risk factors for diabetic retinopathy. Metabolism. 2017;64: 958-966.

36. Wang Z, Cheng Q. Tang K, Sun Y, Zhang K, Zhang Yi.Lipid mediator *Lipoxin* A4 inhibits tumor growth by targetting IL-10-producing regulatory B (Breg) cells. Cancer Letters 2015;364:118–124.

37. Das UN. Lipoxins as biomarkers of lupus and other inflammatory conditions. Das Lipids in Health and Disease 2011; 10:76.

38. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. Jakarta: 2016.p.63-66.

39. European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic methods for the European Union, Stockholm: ECDC; 2016.p.32.

40. International Union Againts Tuberculosis and Lung Disease. Sputum Examination For Tuberculosis by Direct Microscopy in Low Income Countries.5th edition. Franch:2000.p.

41. Siddiqi K, Lambert ML, Walley J.Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. The Lancet Infectious Diseases 2003;3:288.

42. Bouti K, Aharmim M, Marc K, Soualhi M, Zahraoui R, Benamor J, et al. Factors Influencing Sputum Conversion among Smear-Positive Pulmonary Tuberculosis Patients in Morocco.ISRN Pulmonology 2013;p.1-5.

43. Singla R, Osman MM, Khan N, Al-Sharif N, Al-Sayegh MO, Syaikh MA. Factor predicting persistent sputum smear positivity among pulmonary tuberculosis patents 2 months after treatment. Inj J Tuberc Lung Dis 2003;7(1):58-64.

44. Ratnawati, Wijaya D, Nazaruddin AM, Nurwidya F, Burhan E.Relationship between Hemoglobin A1C Levels and Sputum Conversion Time in Indonesian Patients with New Cases of Pulmonary Tuberculosis.J Nat Sc Biol Med 2018;9:217-21.

45. Corona MEJ, Garcia LG, DeRiemer K, Reyes LF, Del-Valle MB, Arellano BC, et al. Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area. *6Thorax*. 2006;61:348–353.

46. Van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco

smoking, HIV and COPD. Eur Respir J. 2010;35(1):27-33. https://doi.org/10.1183/09031936.00072909.

47. North RJ, Jung YJ. Immunity to tuberculosis. Ann Rev Immunol. 2004;22:599-623.https://doi.org/10.1146/annurev. immunol.22.012703.104635.

48. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445- 54. https://doi.org/10.1056/NEJMra0804752.

49. Snider DE Jr. Tuberculosis and body build. JAMA.1987;258:3299.

50. Casha AR, Scarci M. The link between tuberculosis and body mass index. J Thorac Dis. 2017;9(3):E301-E303. doi: 10.21037/jtd.2017.03.47.

51. Comstock GW, Palmer CE. Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis.1966;93:171-83.

52. Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One. 2017;12(4):e0175925. https://doi. org/10.1371/journal.pone.0175925.

53. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737- 46. https://doi.org/10.1016/S1473-3099(09)70282-8.

54. Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr. 2016;4(6):1-19.

55. Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?. BMC Infectious Diseases.2017.17:36.

56. Awji EG, Chand H, Bruse S, Smith KR, Colby JK, Mebratu Y, Levy BD, Tesfaigzi. Wood Smoke Enhances Cigarette Smoke–Induced Inflammation by Inducing the Aryl Hydrocarbon Receptor Repressor in AirwayEpithelial Cells. Am J Respir Cell Mol Biol.2015.52; 377–386.

57. Pavankumar N, Moideen K, Nancy A, Viswanathan V, Shruthi BS, Shanmugam S, et al. Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity are Associated with Lung Pathology and Bacterial Burden.Front. Cell. Infect. Microbiol.2019. 9;335.

58. Gundala, NKV. Anti-inflammatory and anti diabetic action of Arachidonic acid and its metabolite Lipoxin A4. Best popular science story;52-54.

59. Yu D, Xu Z, Yin X, Zheng F, Lin X, Pan Q, et al. Inverse Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a Middle-Aged Chinese Population. PLoS ONE.2015.10 (11): e0142848. doi:10.1371/journal.pone.0142848.

60. Divangahi, M., Desjardins, D., Nunes-Alves, C., Remold, H.G., and Behar, S.M. Eicosanoid pathways regulate adaptive immunity to *Mycobacterium tuberculosis*. *Nat. Immunol*. 2010. 11; 751-758. doi: 10.1038/ni.1904.

61. Tobin, D.M., Roca, F.J., Oh, S.F., McFarland, R., Vickery, T.W., Ray, J.P., et al. Host genotype -specific therapies can optime th inflammatory mediator leukotriene b4 restricts mycobacterial infection. *Plos one*.2013. 8; E67828.

62. Howard NC, Khader SA. Immunometabolism during *Mycobacterium Tuberculosis*Infection. Trends in Microbiology.2020. 20; 19-38.

63. Chen, M. et al.Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 2008.205, 2791.